Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2+ Advanced Breast Cancer|Other Solid Tumors
Interventions: DRUG: Chimeric receptor T-cells + Trastuzumab|DRUG: Fludarabine and Cyclophosphosphamide
Sponsor: National University Hospital, Singapore